These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35631244)

  • 1. From Gut Microbiota through Low-Grade Inflammation to Obesity: Key Players and Potential Targets.
    Vetrani C; Di Nisio A; Paschou SA; Barrea L; Muscogiuri G; Graziadio C; Savastano S; Colao A; On Behalf Of The Obesity Programs Of Nutrition Education Research And Assessment Opera Group
    Nutrients; 2022 May; 14(10):. PubMed ID: 35631244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alteration of intestinal permeability: the missing link between gut microbiota modifications and inflammation in obesity?].
    Genser L; Poitou C; Brot-Laroche É; Rousset M; Vaillant JC; Clément K; Thenet S; Leturque A
    Med Sci (Paris); 2016 May; 32(5):461-9. PubMed ID: 27225918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.
    Amabebe E; Robert FO; Agbalalah T; Orubu ESF
    Br J Nutr; 2020 May; 123(10):1127-1137. PubMed ID: 32008579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota dysbiosis -associated obesity and its involvement in cardiovascular diseases and type 2 diabetes. A systematic review.
    Hamjane N; Mechita MB; Nourouti NG; Barakat A
    Microvasc Res; 2024 Jan; 151():104601. PubMed ID: 37690507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary pulses as a means to improve the gut microbiome, inflammation, and appetite control in obesity.
    John HS; Doucet É; Power KA
    Obes Rev; 2023 Sep; 24(9):e13598. PubMed ID: 37395146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between Gut Microbiota, Gut Hyperpermeability and Obesity.
    Gasmi A; Mujawdiya PK; Pivina L; Doşa A; Semenova Y; Benahmed AG; Bjørklund G
    Curr Med Chem; 2021; 28(4):827-839. PubMed ID: 32693755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the gut microbiota on inflammation, obesity, and metabolic disease.
    Boulangé CL; Neves AL; Chilloux J; Nicholson JK; Dumas ME
    Genome Med; 2016 Apr; 8(1):42. PubMed ID: 27098727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction between microbiome and host central nervous system: the gut-brain axis as a potential new therapeutic target in the treatment of obesity and cardiometabolic disease.
    Wijdeveld M; Nieuwdorp M; IJzerman R
    Expert Opin Ther Targets; 2020 Jul; 24(7):639-653. PubMed ID: 32441559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2'-fucosyllactose Supplementation Improves Gut-Brain Signaling and Diet-Induced Obese Phenotype and Changes the Gut Microbiota in High Fat-Fed Mice.
    Lee S; Goodson M; Vang W; Kalanetra K; Barile D; Raybould H
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32260563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review.
    Dai Y; Shen Z; Khachatryan LG; Vadiyan DE; Karampoor S; Mirzaei R
    Pathol Res Pract; 2023 Sep; 249():154740. PubMed ID: 37567034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut.
    Mishra SP; Wang B; Jain S; Ding J; Rejeski J; Furdui CM; Kitzman DW; Taraphder S; Brechot C; Kumar A; Yadav H
    Gut; 2023 Oct; 72(10):1848-1865. PubMed ID: 36948576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering the Gut Microbiome for Treatment of Obesity: A Review of Current Understanding and Progress.
    Lim YY; Lee YS; Ooi DSQ
    Biotechnol J; 2020 Oct; 15(10):e2000013. PubMed ID: 32663372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gut microbiota and immune crosstalk in metabolic disease].
    Burcelin R
    Biol Aujourdhui; 2017; 211(1):1-18. PubMed ID: 28682223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
    Rizzetto L; Fava F; Tuohy KM; Selmi C
    J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of gut microbiota on diabetes mellitus.
    Blandino G; Inturri R; Lazzara F; Di Rosa M; Malaguarnera L
    Diabetes Metab; 2016 Nov; 42(5):303-315. PubMed ID: 27179626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut Microbiota Mediates the Protective Effects of Dietary Capsaicin against Chronic Low-Grade Inflammation and Associated Obesity Induced by High-Fat Diet.
    Kang C; Wang B; Kaliannan K; Wang X; Lang H; Hui S; Huang L; Zhang Y; Zhou M; Chen M; Mi M
    mBio; 2017 May; 8(3):. PubMed ID: 28536285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis.
    Ahmadi S; Razazan A; Nagpal R; Jain S; Wang B; Mishra SP; Wang S; Justice J; Ding J; McClain DA; Kritchevsky SB; Kitzman D; Yadav H
    J Gerontol A Biol Sci Med Sci; 2020 Jun; 75(7):e9-e21. PubMed ID: 32129462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk.
    Murphy EA; Velazquez KT; Herbert KM
    Curr Opin Clin Nutr Metab Care; 2015 Sep; 18(5):515-20. PubMed ID: 26154278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies.
    van den Munckhof ICL; Kurilshikov A; Ter Horst R; Riksen NP; Joosten LAB; Zhernakova A; Fu J; Keating ST; Netea MG; de Graaf J; Rutten JHW
    Obes Rev; 2018 Dec; 19(12):1719-1734. PubMed ID: 30144260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes.
    Scheithauer TPM; Rampanelli E; Nieuwdorp M; Vallance BA; Verchere CB; van Raalte DH; Herrema H
    Front Immunol; 2020; 11():571731. PubMed ID: 33178196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.